title: Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia.
abstract: BACKGROUND
  Current results of autologous bone marrow transplantation (ABMT) suggest that this procedure may prolong disease-free survival (DFS) in patients with acute myeloid leukemia (AML).
  
  
  METHODS
  Over the last ten years, 29 AML patients received unpurged autologous bone marrow (BM) after a conditioning regimen including Ara-C (3 g/m2/12h, days -9, -8), CTX (60 mg/kg/day, days -6, -5) and TBI (3.33 Gy/day, days -3 through -1). In 21 patients, ABMT was performed as late intensification after first CR. Eight more relapsing patients were autografted after the achievement of second CR.
  
  
  RESULTS
  Three patients died from transplant-related complications. In the remaining patients, mean times to WBC and platelet recovery were, respectively, 23 days (range 13-55) and 55 days (range 22-790). Follow-up for censored patients ranged from 1 to 120 months. Relapse occurred in 7 patients (5 in first and 2 in second CR). Overall 5-year DFS and event-free survival (EFS) chances were, respectively, 67.3% and 60%, with no statistically significant differences between first (DFS = 67.3%, EFS = 60.3%) and second CR (DFS = 68.6%, EFS = 60%).
  
  
  CONCLUSIONS
  Apart from obvious selection biases, our study suggests that outcome in first CR AML patients is improved by ABMT. Long-term DFS and EFS are clearly better than when conventional post-remission chemotherapies are used. The greater antileukemic potential of ABMT is further underlined by the results in patients autografted in second CR, when conventional chemotherapy is almost never curative.
authors.affiliation: Centro Trapianti di Midollo, Ospedale Maggiore di Milano, I.R.C.C.S. Università degli Studi di Milano, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Lambertenghi Deliliers
authors.forename: C
authors.initials: C
authors.lastname: Annaloro
authors.forename: A
authors.initials: A
authors.lastname: Della Volpe
authors.forename: A
authors.initials: A
authors.lastname: Oriani
authors.forename: R
authors.initials: R
authors.lastname: Mozzana
authors.forename: E
authors.initials: E
authors.lastname: Pozzoli
authors.forename: E
authors.initials: E
authors.lastname: Tagliaferri
authors.forename: D
authors.initials: D
authors.lastname: Soligo
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000401:mortality; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome